- Home
- GERN vs TNGX Comparison
GERN vs TNGX Comparison
Compare GERN & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- TNGX
- Stock Information
- Founded
- GERN 1990
- TNGX 2014
- Country
- GERN United States
- TNGX United States
- Employees
- GERN 229
- TNGX N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- GERN Health Care
- TNGX Health Care
- Exchange
- GERN Nasdaq
- TNGX Nasdaq
- Market Cap
- GERN 823.0M
- TNGX 723.2M
- IPO Year
- GERN 1996
- TNGX N/A
- Fundamental
- Price
- GERN $1.30
- TNGX $6.65
- Analyst Decision
- GERN Buy
- TNGX Strong Buy
- Analyst Count
- GERN 8
- TNGX 6
- Target Price
- GERN $3.71
- TNGX $10.00
- AVG Volume (30 Days)
- GERN 6.6M
- TNGX 1.3M
- Earning Date
- GERN 11-06-2025
- TNGX 11-05-2025
- Dividend Yield
- GERN N/A
- TNGX N/A
- EPS Growth
- GERN N/A
- TNGX N/A
- EPS
- GERN N/A
- TNGX N/A
- Revenue
- GERN $164,447,000.00
- TNGX $24,296,000.00
- Revenue This Year
- GERN $175.15
- TNGX $6.56
- Revenue Next Year
- GERN $56.61
- TNGX N/A
- P/E Ratio
- GERN N/A
- TNGX N/A
- Revenue Growth
- GERN 11877.20
- TNGX N/A
- 52 Week Low
- GERN $1.09
- TNGX $1.03
- 52 Week High
- GERN $4.83
- TNGX $10.85
- Technical
- Relative Strength Index (RSI)
- GERN 42.28
- TNGX 49.24
- Support Level
- GERN $1.27
- TNGX $6.25
- Resistance Level
- GERN $1.52
- TNGX $7.40
- Average True Range (ATR)
- GERN 0.06
- TNGX 0.40
- MACD
- GERN -0.02
- TNGX -0.05
- Stochastic Oscillator
- GERN 8.00
- TNGX 33.04
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.